Recurrent Bleeding, Survival, and Longitudinal Pulmonary Function following Bronchial Artery Embolization for Hemoptysis in a U.S. Adult Population

Bronchial artery embolization in hemoptysis: a systematic review

“…We also excluded five studies whose full-texts were not available despite our best efforts. Finally, there were 22 studies (5)(6)(7)(8)(9)(10)(11)(12)(13)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27) meeting the selection criteria for this systematic review. The search strategy is schematized in Fig.…”

“…In fact, a few studies reported the role of BAE exclusively in patients with active TB and/or post-TB sequelae (9,18,21,25,27). On the other hand, malignancies, nontubercular mycobacterial infections, lung abscesses, vasculitis, and cryptogenic hemoptysis were Bronchial artery embolization in hemoptysis • 309 more common in studies published from Western population (8,12). In the study by Tom et al (12), which reported BAE experience in 69 patients from the United States, sarcoidosis and cystic fibrosis were the most common indications, comprising 36% of patient population while TB and post-TB sequelae formed only 8% of the patient population.…”

“…On the other hand, malignancies, nontubercular mycobacterial infections, lung abscesses, vasculitis, and cryptogenic hemoptysis were Bronchial artery embolization in hemoptysis • 309 more common in studies published from Western population (8,12). In the study by Tom et al (12), which reported BAE experience in 69 patients from the United States, sarcoidosis and cystic fibrosis were the most common indications, comprising 36% of patient population while TB and post-TB sequelae formed only 8% of the patient population. Similarly, cystic fibrosis formed 16% of patients in the study by Fruchter et al (9) compared with only 2% incidence of post-tubercular sequelae.…”

“…Technical success, i.e., the ability to cannulate and embolize all visualized abnormal arteries varied from 81% to 100% (6,10,12,18,20,23). Causes of technical failure included uncooperative patient or patient condition not permitting BAE, artery Embolizing agents: The choice of embolizing agents also evolved over the years.…”

“…Few authors also used microspheres in the size range of 100-900 μm and 250-1300 μm (9,12). Microspheres are hydrophilic and are more uniform in size compared with PVA and thus less prone for clumping within catheters (3).…”